Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eleison's ILC Receives Orphan Status from EC | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Eleison’s ILC Receives Orphan Status from EC

Osteosarcoma drug to enter Phase II in 2014

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Eleison Pharmaceuticals has received Orphan Drug Designation for ILC (Inhaled Lipid-complexed Cisplatin) from the European Commission, for the treatment of osteosarcoma. The designation follows the earlier positive opinion and recommendation of the European Medicines Agency (EMA) Committee of Orphan Medical Products.

Orphan Drug Designation provides Eleison access to protocol assistance and certain financial incentives from the EMA, as well as 10 years marketing exclusivity for ILC upon the receipt of marketing approval.

Dr. Forrest Anthony, chief medical officer of Eleison, commented, “We are very pleased to receive Orphan Drug Designation by the European Commission, as ILC is potentially a breakthrough in the treatment of children and young adults with osteosarcoma, an often deadly cancer with little improvement in survival over the past 25 years. Our global Phase II clinical for ILC remains ongoing with interim results expected in the middle of next year.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics